Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid DNA Sequencing Technology Could Improve Treatment for Fracture-Related Infections

By LabMedica International staff writers
Posted on 12 Jun 2025

Fracture-related infections are a serious complication after broken bone surgeries, potentially arising at any point during treatment. More...

These infections can significantly prolong recovery, impair bone healing, cause permanent disability or even amputation, and often require repeated surgeries, costing the healthcare system billions annually. Despite progress in orthopedic trauma care, treatment for these infections still fails in about 30% of cases. Now, a new multicenter clinical trial is evaluating whether rapid next-generation DNA sequencing can improve patient outcomes and reduce the rate of treatment failure and recurrent infection.

The study, led by researchers at Indiana University School of Medicine (Indianapolis, IN, USA), is being conducted through the Major Extremity Trauma Research Consortium, which comprises over 80 trauma centers across the U.S. and Canada. The research spans 15 clinical sites and will follow 250 patients, aged 18 to 84, over the course of four years. It brings together a multidisciplinary team of experts in trauma, infectious diseases, and molecular diagnostics. Unlike traditional diagnostic methods such as polymerase chain reaction (PCR) and culture tests — which are limited in their ability to detect a broad range of pathogens — next-generation sequencing reads microbial DNA to comprehensively identify bacteria and fungi present in a sample. This technology offers a more detailed and faster analysis of the infectious agents responsible for complications following orthopedic surgery.

Patients enrolled in the trial will receive standard care alongside next-generation sequencing diagnostics provided by industry partner MicroGenDX (Orlando, FL, USA). Hospital-based infectious disease specialists will use these sequencing results to tailor antibiotic treatment plans for each patient. Treatment effectiveness will then be monitored for one year, aligning with standard care protocols. If successful, this study could transform the management of fracture-related infections by enabling earlier, more precise interventions. Improved diagnostics may lead to fewer re-hospitalizations, less need for repeat surgeries or amputations, more survivors, and major cost savings for healthcare systems. Researchers believe next-generation sequencing may give clinicians more information to help them decide what the best course of action is for individual patients.

"We hope to get more information from the next-generation sequencing diagnostics that will uncover pathogens that would have not been identified by our current standard tools," said Roman M. Natoli, MD, PhD, associate professor of orthopedic surgery in the Department of Orthopedic Surgery at IU School of Medicine and principal investigator of the clinical trial. "This trial will allow us to choose more appropriate antibiotic treatment via next-generation sequencing results and ultimately, if we're correct, reduce the rate of failure for treating patients that have infections after fractures. We hope to not only reduce the failure rate in fracture-related infections but also bring wounded warriors and civilians to more optimal function, where they can return to active duty, work and life."

Related Links:
Indiana University School of Medicine
MicroGenDX


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.